Effect of intra-aortic balloon pump on in-hospital mortality in acute myocardial infarction complicating cardiogenic shock at different stages

BACKGROUND: In 2012, the randomised trial IABP SHOCK II demonstrated that IABP did not reduce 30-day mortality in patients with acute myocardial infarction complicating cardiogenic shock (CS). However, SCAI proposed a new standardised classification of cardiogenic shock in 2019. It is reasonably hypothesised that the use of IABP may have different benefits for patients in different stages of CS. METHODS: = 32). In-hospital mortality was compared between using and without using IABP at each stage. RESULTS: = .414). CONCLUSIONS: For patients with acute myocardial infarction complicating cardiogenic shock, IABP has no effect on in-hospital mortality in SCAI stages B, D, and E. However, in SCAI stage C, IABP can reduce in-hospital mortality.